...
首页> 外文期刊>Bipolar disorders. >Risk of recurrence after a single manic or mixed episode – a systematic review and meta‐analysis
【24h】

Risk of recurrence after a single manic or mixed episode – a systematic review and meta‐analysis

机译:单一贩卖疾病或混合发作后复发风险 - 系统审查和荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

Abstract Objectives For the first time to estimate the risk of recurrence among patients with a single manic/mixed episode by systematically reviewing prior studies on cohorts of adults, and cohorts of children and adolescents, respectively. Methods A systematic literature search up to August 2017 was carried out including studies in which 25% of the participants were estimated to have had a mood episode that required pharmacological treatment prior to the index manic or mixed episode at inclusion. Results Three studies including a total of 293 adult patients with a single manic or mixed episode and three studies of children and adolescents including 126 patients were identified. In the adult studies, 31%, 40% and 42% experienced recurrence after recovery within 1?year, 59% after 2?years, and 58% after 4?years, respectively. In the studies on children and adolescents, 40% and 52% experienced recurrence after recovery within 1?year, 30% and 60% after 2?years and 64% and 67% after 4 to 5?years, respectively. Results from meta‐analyses showed a 1‐year rate of recurrence of 35% (95% confidence interval [ CI ]: 30‐41%) in adults, and in adolescents/children, a 1‐year rate of recurrence of 48% (95% CI : 38‐58%), a 2‐year rate of 46% (95% CI : 33‐60%) and a 4‐5‐year rate of recurrence of 65% (95% CI : 52‐77%; as data from different studies were included at 1, 2 and 5?years, rates of recurrence did not increase steadily with time). Conclusions The rate of recurrence is high among adults as well as children and adolescents. It is important that clinicians and patients as well as relatives are well informed about these high risks when deciding to start maintenance treatment or not following onset of a single manic or mixed episode.
机译:摘要目的首次估算单一贩卖患者复发的风险,通过系统地审查关于成人群组和儿童和青少年的群组的先前研究。方法进行2017年8月的系统文献搜索,包括研究,其中&估计有25%的参与者有一种情绪发作,可在甲状腺指标或混合发作之前所需的药理学治疗。结果鉴定了三项研究,包括共有293名成年患者的293名成年患者以及包含126名患者的儿童和青少年的三项研究。在成人研究中,在1年内恢复后的31%,40%和42%经历的复发,2?年后59%,分别为58%,分别为58%。在儿童和青少年的研究中,在1年内恢复后的40%和52%的复发后,2岁以下的30%和60%,分别在4到5年后64%和67%。荟萃分析的结果表明,成人中的35%(95%置信区间:30-41%)和青少年/儿童的速度为35%(95%:30-41%),均为48%的1年( 95%CI:38-58%),2年率为46%(95%CI:33-60%)和4-5年复发率为65%(95%CI:52-77% ;由于来自不同研究的数据包括在1,2和5?年内,复发率并没有随时间稳步增加)。结论成年人和儿童和青少年的复发率很高。重要的是,当决定开始维护治疗或未在单个躁狂或混合发作后开始,临床医生和患者以及亲属都会得到很好的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号